These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 27745715)

  • 1. Selecting initial treatment of acute myeloid leukaemia in older adults.
    Podoltsev NA; Stahl M; Zeidan AM; Gore SD
    Blood Rev; 2017 Mar; 31(2):43-62. PubMed ID: 27745715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.
    Kantarjian HM; Roboz GJ; Kropf PL; Yee KWL; O'Connell CL; Tibes R; Walsh KJ; Podoltsev NA; Griffiths EA; Jabbour E; Garcia-Manero G; Rizzieri D; Stock W; Savona MR; Rosenblat TL; Berdeja JG; Ravandi F; Rock EP; Hao Y; Azab M; Issa JJ
    Lancet Oncol; 2017 Oct; 18(10):1317-1326. PubMed ID: 28844816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
    Seymour JF; Döhner H; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Del Castillo TB; Al-Ali HK; Falantes J; Stone RM; Minden MD; Weaver J; Songer S; Beach CL; Dombret H
    BMC Cancer; 2017 Dec; 17(1):852. PubMed ID: 29241450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?
    Ferrara F
    Hematol Oncol; 2014 Mar; 32(1):1-9. PubMed ID: 23512815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia.
    Talati C; Lancet JE
    Future Oncol; 2018 May; 14(12):1147-1154. PubMed ID: 29378418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute myeloid leukemia in the elderly: therapeutic options and choice.
    Webster JA; Pratz KW
    Leuk Lymphoma; 2018 Feb; 59(2):274-287. PubMed ID: 28573892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial therapy for acute myeloid leukemia in older patients: principles of care.
    Bhatt VR; Gundabolu K; Koll T; Maness LJ
    Leuk Lymphoma; 2018 Jan; 59(1):29-41. PubMed ID: 28573900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.
    Krug U; Röllig C; Koschmieder A; Heinecke A; Sauerland MC; Schaich M; Thiede C; Kramer M; Braess J; Spiekermann K; Haferlach T; Haferlach C; Koschmieder S; Rohde C; Serve H; Wörmann B; Hiddemann W; Ehninger G; Berdel WE; Büchner T; Müller-Tidow C; ;
    Lancet; 2010 Dec; 376(9757):2000-8. PubMed ID: 21131036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
    Kadia TM; Faderl S; Ravandi F; Jabbour E; Garcia-Manero G; Borthakur G; Ferrajoli A; Konopleva M; Burger J; Huang X; Wang X; Pierce S; Brandt M; Feliu J; Cortes J; Kantarjian H
    Cancer; 2015 Jul; 121(14):2375-82. PubMed ID: 25809968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.
    Ravandi F; Ritchie EK; Sayar H; Lancet JE; Craig MD; Vey N; Strickland SA; Schiller GJ; Jabbour E; Erba HP; Pigneux A; Horst HA; Recher C; Klimek VM; Cortes J; Roboz GJ; Odenike O; Thomas X; Havelange V; Maertens J; Derigs HG; Heuser M; Damon L; Powell BL; Gaidano G; Carella AM; Wei A; Hogge D; Craig AR; Fox JA; Ward R; Smith JA; Acton G; Mehta C; Stuart RK; Kantarjian HM
    Lancet Oncol; 2015 Sep; 16(9):1025-1036. PubMed ID: 26234174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The response to induction therapy is crucial for the treatment outcomes of elderly patients with acute myeloid leukemia: single-institution experience.
    Tasaki T; Yamauchi T; Matsuda Y; Takai M; Ookura M; Lee S; Tai K; Ikegaya S; Kishi S; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
    Anticancer Res; 2014 Oct; 34(10):5631-6. PubMed ID: 25275066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute myeloid leukemia transformed to a targetable disease.
    Saleh K; Khalifeh-Saleh N; Kourie HR
    Future Oncol; 2020 May; 16(14):961-972. PubMed ID: 32297538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of patients aged 60-75 years with newly diagnosed secondary acute myeloid leukemia: A single-institution experience.
    Bertoli S; Tavitian S; Bories P; Luquet I; Delabesse E; Comont T; Sarry A; Huguet F; Bérard E; Récher C
    Cancer Med; 2019 Jul; 8(8):3846-3854. PubMed ID: 31173485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. More Versus Less Therapy for Older Adults With Acute Myeloid Leukemia: New Perspectives on an Old Debate.
    Klepin HD; Estey E; Kadia T
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():421-432. PubMed ID: 31099627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
    Mawad R; Becker PS; Hendrie P; Scott B; Wood BL; Dean C; Sandhu V; Deeg HJ; Walter R; Wang L; Myint H; Singer JW; Estey E; Pagel JM
    Br J Haematol; 2016 Jan; 172(2):238-45. PubMed ID: 26568032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.
    Park H; Youk J; Kim I; Yoon SS; Park S; Lee JO; Bang SM; Koh Y
    Ann Hematol; 2016 Oct; 95(11):1777-86. PubMed ID: 27539617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are we curing more older adults with acute myeloid leukemia with allogeneic transplantation in CR1?
    Finn LE; Foran JM
    Curr Opin Hematol; 2016 Mar; 23(2):95-101. PubMed ID: 26825695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
    Issa JJ; Roboz G; Rizzieri D; Jabbour E; Stock W; O'Connell C; Yee K; Tibes R; Griffiths EA; Walsh K; Daver N; Chung W; Naim S; Taverna P; Oganesian A; Hao Y; Lowder JN; Azab M; Kantarjian H
    Lancet Oncol; 2015 Sep; 16(9):1099-1110. PubMed ID: 26296954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records From US Community Oncology Practices.
    Ma E; Bonthapally V; Chawla A; Lefebvre P; Swords R; Lafeuille MH; Fortier J; Emond B; Duh MS; Dezube BJ
    Clin Lymphoma Myeloma Leuk; 2016 Nov; 16(11):625-636.e3. PubMed ID: 27686689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute myeloid leukemia in older adults.
    Yanada M; Naoe T
    Int J Hematol; 2012 Aug; 96(2):186-93. PubMed ID: 22791510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.